Treatment outcome in adults with acute lymphoblastic leukemia: 50% long-term disease-free survival. 2007

G E Tjønnfjord, and T Gedde-Dahl, and D Heldal, and L Brinch

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

G E Tjønnfjord, and T Gedde-Dahl, and D Heldal, and L Brinch
February 1985, Cancer treatment reports,
G E Tjønnfjord, and T Gedde-Dahl, and D Heldal, and L Brinch
January 1988, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
G E Tjønnfjord, and T Gedde-Dahl, and D Heldal, and L Brinch
June 1981, Blood,
G E Tjønnfjord, and T Gedde-Dahl, and D Heldal, and L Brinch
January 1988, Medical and pediatric oncology,
G E Tjønnfjord, and T Gedde-Dahl, and D Heldal, and L Brinch
August 2017, Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,
G E Tjønnfjord, and T Gedde-Dahl, and D Heldal, and L Brinch
December 1990, British journal of haematology,
G E Tjønnfjord, and T Gedde-Dahl, and D Heldal, and L Brinch
August 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
G E Tjønnfjord, and T Gedde-Dahl, and D Heldal, and L Brinch
January 1988, Archiv fur Geschwulstforschung,
G E Tjønnfjord, and T Gedde-Dahl, and D Heldal, and L Brinch
July 1983, Cancer,
Copied contents to your clipboard!